XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $3.32M invested in XTL Biopharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
1,168% more capital invested
Capital invested by funds: $262K → $3.32M (+$3.06M)
4.85% more ownership
Funds ownership: 0.49% → 5.34% (+4.8%)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.87M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
XTLB Hedge Fund Activity: Q1 2015 in Review
3 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2015, worth a combined $3.32M — up 1,168% from $262K a quarter earlier.
Fund positioning in XTLB was balanced in Q1 2015: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.87M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $2K sold.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2015, unchanged from Q4 2014.
- Funds reported $3.32M of XTL Biopharmaceuticals stock for Q1 2015, up 1,168% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q1 2015 and 1 closed out, a net change of 0 holders.
- The largest XTL Biopharmaceuticals buyer in Q1 2015 was Sabby Management, an estimated $2.87M added.
- The largest XTL Biopharmaceuticals seller in Q1 2015 was Tower Research Capital (TRC), an estimated $2K sold.
Based on aggregated 13F filings for Q1 2015.